Skip to main content
. 2020 Dec 17;9(3):648–658. doi: 10.1016/j.gendis.2020.12.005

Table 3.

Molecular markers status and suggestive therapies of breast cancer.

Status of molecular markers
Hormone positive Hormone negative HER2 positive HER2 negative Triple negative
Hormone therapy Premenopausal
  • 1.
    Estrogen-receptor modulators
    • i.
      Tamoxifen
    • ii.
      Toremifene
  • 2.
    Selective estrogen receptor degrader
    • i.
      Fulvestrant
  • 3.

    Luteinizing hormone-releasing hormone agents (LHRHs)

Targeted therapy
  • 4.
    Cyclin-dependent kinases (CDKs) 4/6 inhibitors
    • i.
      Palbociclib
    • ii.
      Ribociclib
    • iii.
      Abemaciclib
Postmenopausal
  • 5.
    Aromatase inhibitors
    • i.
      Anastrozole
    • ii.
      Letrozole
    • iii.
      Exemestane
    • iv.
      Goserelin
    • v.
      Leuprolide
 Chemotherapy
  • 1.

    Doxorubicin

  • 2.

    Epirubicin

  • 3.

    Paclitaxel

  • 4.

    Docetaxel

  • 5.

    5-fluorouracil

  • 6.

    Cyclophosphamide

  • 7.

    Carboplatin

  • 8.

    albumin-bound paclitaxel

  • 9.

    Anthracyclines

  • 10.

    Platinum agents

  • 11.

    Vinorelbine

  • 12.

    Capecitabine

  • 13.

    Gemcitabine

  • 14.

    Ixabepilone

  • 15.

    Eribulin

 Targeted therapy Monoclonal antibody
  • 1.

    Trastuzumab

  • 2.

    Pertuzumab

  • 3.

    Ado-trastuzumab emtansine

Kinase inhibitor
  • 1.

    Lapatinib

  • 2.

    Neratinib

 Targeted therapy
  • 1.

    Everolimus

  • 2.

    Olaparib

  • 3.

    Talazoparib

 Immunotherapy PD-L1 inhibitors
  • 1.

    Atezolizumab Chemotherapy for hormone negative in combination with targeted therapy for HER2 negative